Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Ascendis Pharma A (ASND) over the last 14 years, with Q3 2025 value amounting to $4.4 million.

  • Ascendis Pharma A's Goodwill & Intangibles fell 298.68% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 298.68%. This contributed to the annual value of $4.4 million for FY2024, which is 830.61% down from last year.
  • According to the latest figures from Q3 2025, Ascendis Pharma A's Goodwill & Intangibles is $4.4 million, which was down 298.68% from $4.3 million recorded in Q2 2025.
  • Ascendis Pharma A's Goodwill & Intangibles' 5-year high stood at $6.8 million during Q1 2021, with a 5-year trough of $4.1 million in Q1 2025.
  • In the last 5 years, Ascendis Pharma A's Goodwill & Intangibles had a median value of $4.9 million in 2022 and averaged $5.1 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Goodwill & Intangibles surged by 7526.42% in 2021, and later plummeted by 2156.8% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Goodwill & Intangibles stood at $6.0 million in 2021, then fell by 18.33% to $4.9 million in 2022, then fell by 3.48% to $4.8 million in 2023, then dropped by 9.47% to $4.3 million in 2024, then grew by 1.63% to $4.4 million in 2025.
  • Its Goodwill & Intangibles was $4.4 million in Q3 2025, compared to $4.3 million in Q2 2025 and $4.1 million in Q1 2025.